Maytansinoid Derivative Conjugates for Selective Cytotoxic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for proliferative diseases, such as cancer, often indiscriminately target both normal and abnormal cells, leading to significant side effects, while targeted drug delivery systems like antibody-drug conjugates (ADCs) face challenges in specificity and efficacy.
Innovation Solution
Development of maytansinoid derivatives conjugated with binding agents through linkers, forming compounds of specific formulas that enhance targeted delivery of cytotoxic agents to abnormal cells, utilizing arylene or heteroarylene structures and various linkers to improve specificity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy drugs are used to treat proliferative diseases, then the spread of abnormal cells is limited, but both normal and abnormal cells are affected causing significant side effects
Solution Approach 1:
The chemotherapy treatment is segmented into two distinct components: a targeting moiety that specifically binds to abnormal cells and a cytotoxic agent that kills the cells. This segmentation allows the cytotoxic agent to be delivered only to abnormal cells through the selective binding of the targeting moiety, thereby maintaining efficacy while reducing side effects on normal cells.
Solution Approach 2:
A linking moiety serves as an intermediary between the targeting moiety and the cytotoxic agent. This intermediary component enables the specific delivery of the cytotoxic agent to abnormal cells by connecting it to the targeting moiety, ensuring that the harmful cytotoxic effect is mediated only through the specific binding to abnormal cells rather than affecting normal cells.
2Measurement precision
If antibody-drug conjugates are used for targeted delivery, then selectivity for abnormal cells is improved, but challenges remain in achieving sufficient specificity and efficacy
Solution Approach 1:
The invention employs multiple parameters that can be optimized to achieve both high specificity and efficacy: (1) selecting targeting moieties with high binding affinity and specificity for abnormal cells, (2) choosing cytotoxic agents with appropriate potency levels, (3) optimizing the linking moiety structure for stable yet deliverable connection, and (4) adjusting the stoichiometric ratio of targeting moiety to cytotoxic agent to achieve optimal therapeutic effect while maintaining specificity.
Data Source
AI summary
Provided herein are maytansinoid derivatives, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.